Latest Xtl Biopharma Ads (XTLB) Headlines XTL Bio
Post# of 22
Posted On: 03/12/2014 5:05:43 AM
Latest Xtl Biopharma Ads (XTLB) Headlines
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus
PR Newswire - Wed Jan 08, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus (SLE).
XTL Biopharmaceuticals' ADRs Commence Trading on NASDAQ Stock Market
PR Newswire - Mon Jul 15, 12:30PM CDT
XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL) (the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs, today announced that its ADRs began trading on NASDAQ today, July 15, 2013 under the ticker symbol "XTLB".
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus
PR Newswire - Wed Jan 08, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus (SLE).
XTL Biopharmaceuticals' ADRs Commence Trading on NASDAQ Stock Market
PR Newswire - Mon Jul 15, 12:30PM CDT
XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL) (the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs, today announced that its ADRs began trading on NASDAQ today, July 15, 2013 under the ticker symbol "XTLB".
(0)
(0)